{"id":3340,"date":"2018-10-09T17:07:00","date_gmt":"2018-10-09T11:37:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3340"},"modified":"2021-07-24T12:57:05","modified_gmt":"2021-07-24T07:27:05","slug":"notizia-75","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-75","title":{"rendered":"Notizia"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>FDA approves <\/strong><strong>transthyretin amyloidosis therapy of Akcea, Ionis<\/strong><\/p>\n<p style=\"text-align: justify;\">Patients with an <strong>orphan<\/strong>, hereditary disease that is <a href=\"https:\/\/www.delveinsight.com\/report-store\/transthyretin-amyloidosis-attr-market-2027\"><strong>transthyretin amyloidosis<\/strong> <\/a>with a second new treatment option are available after the <strong>Food and Drug Administration<\/strong> approved <strong>Akcea Therapeutics<\/strong> and <strong>Ionis Pharmaceuticals&#8217;\u00a0<\/strong>Tegsedi.\u00a0 As Tegsedi is approved, Akcea squarely faces competition with Alnylam Pharmaceuticals, which got an approval from the FDA formerly for its drug <strong>Onpattro<\/strong>. Both therapies target RNA, degrading the genetic instructions that are responsible for the production of a misfolded protein, which builds up in the organs of patients with the disease.<\/p>\n<p style=\"text-align: justify;\"><strong>Prenatal inflammation is a probable answer to why some infants are more prone to neonatal sepsis<\/strong><\/p>\n<p style=\"text-align: justify;\">Millions of infants are born before term and suffer high risks of short- and long-term complications that include sepsis, <strong>severe gut inflammation<\/strong>, and <strong>neurodevelopmental disorders<\/strong>. The\u00a0<strong>American Journal of Pathology<\/strong> shows in the report regarding a link between <strong>prenatal inflammation<\/strong> and <strong>postnatal immune<\/strong> status and organ function in preterm pigs, giving cues that early intervention (like antibiotics or anti-inflammatory drugs) might be justified for infants born preterm with signs of inflammation of fetal membranes.<\/p>\n<p style=\"text-align: justify;\"><strong>Merck receives <\/strong><strong>extended approval of Gardasil <\/strong><\/p>\n<p style=\"text-align: justify;\">The <strong>Food and Drug Administration<\/strong> has extended the approval of <strong>Gardasil 9 vaccine<\/strong> of <strong>Merck &amp; Co<\/strong>. It is a boost for the company and adults, who are looking to prevent <a href=\"https:\/\/www.delveinsight.com\/report-store\/human-papillomavirus-hpv-market\"><strong>human papillomavirus (HPV) infection<\/strong><\/a>. The vaccine covers people of ages between <strong>27 and 45 years<\/strong>. Gardasil-9 covers nine different subtypes of HPV and is now available for use in in the U.S. in males and females aged between nine and 26 years.<\/p>\n<p style=\"text-align: justify;\"><strong>Experts apprise of serious harm to UK cancer research <\/strong><\/p>\n<p style=\"text-align: justify;\">Cancer experts apprise of <strong>Brexit<\/strong> seriously harming <strong>UK cancer research<\/strong> and could prompt a manpower crisis that will ensue repercussions to the health of the citizens. Researchers from <strong>Queen&#8217;s University Belfast<\/strong> in collaboration with <strong>King&#8217;s College London<\/strong> and the <strong>University of Leeds<\/strong> have shown the positive benefit that researchers from other <strong>European Union (EU)<\/strong> countries presently have on cancer research in the UK. <strong>The Lancet Oncology<\/strong>, the study, which was recently published in the premier cancer journal, showed that there have been growing number of scientific papers on cancer published by research teams that include at least one non-UK EU born member of staff.<\/p>\n<p style=\"text-align: justify;\">\n","protected":false},"excerpt":{"rendered":"<p>FDA approves transthyretin amyloidosis therapy of Akcea, Ionis Patients with an orphan, hereditary disease that is transthyretin amyloidosis with a second new treatment option are available after the Food and Drug Administration approved Akcea Therapeutics and Ionis Pharmaceuticals&#8217;\u00a0Tegsedi.\u00a0 As Tegsedi is approved, Akcea squarely faces competition with Alnylam Pharmaceuticals, which got an approval from the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3366,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1941,1482,1936,786,1951,704,1940,1944,1946,1437,1949,1945,1935,1943,439,1938,1937,1948,1934,1942,1952,1939,1947,1950],"industry":[17225],"therapeutic_areas":[17240,17227,17231,17278,17234],"class_list":["post-3340","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-akcea-therapeutics","tag-alnylam-pharmaceuticals","tag-american-journal-of-pathology","tag-brexit","tag-european-union-eu","tag-fda","tag-food-and-drug-administration","tag-gardasil-9-vaccine","tag-human-papillomavirus-hpv-infection","tag-ionis-pharmaceuticals","tag-kings-college-london","tag-merck-co","tag-neurodevelopmental-disorders","tag-onpattro","tag-orphan","tag-postnatal-immune","tag-prenatal-inflammation","tag-queens-university-belfast","tag-severe-gut-inflammation","tag-tegsedi","tag-the-lancet-oncology","tag-transthyretin-amyloidosis","tag-uk-cancer-research","tag-university-of-leeds","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-infectious-diseases","therapeutic_areas-other-diseases","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notizia 09\/10\/2018 - DelveInsight Business Research LLP<\/title>\n<meta name=\"description\" content=\"Patients with an orphan, hereditary disease that is transthyretin amyloidosis now with a second new treatment option are available when the....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-75\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Notizia 09\/10\/2018 - DelveInsight Business Research LLP\" \/>\n<meta property=\"og:description\" content=\"Patients with an orphan, hereditary disease that is transthyretin amyloidosis now with a second new treatment option are available when the....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-75\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-10-09T11:37:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022610\/edited-notizia.png\" \/>\n\t<meta property=\"og:image:width\" content=\"686\" \/>\n\t<meta property=\"og:image:height\" content=\"350\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Notizia 09\/10\/2018 - DelveInsight Business Research LLP","description":"Patients with an orphan, hereditary disease that is transthyretin amyloidosis now with a second new treatment option are available when the....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-75","og_locale":"en_US","og_type":"article","og_title":"Notizia 09\/10\/2018 - DelveInsight Business Research LLP","og_description":"Patients with an orphan, hereditary disease that is transthyretin amyloidosis now with a second new treatment option are available when the....","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-75","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-10-09T11:37:00+00:00","article_modified_time":"2021-07-24T07:27:05+00:00","og_image":[{"width":686,"height":350,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022610\/edited-notizia.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-75","url":"https:\/\/www.delveinsight.com\/blog\/notizia-75","name":"Notizia 09\/10\/2018 - DelveInsight Business Research LLP","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-75#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-75#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022610\/edited-notizia.png","datePublished":"2018-10-09T11:37:00+00:00","dateModified":"2021-07-24T07:27:05+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Patients with an orphan, hereditary disease that is transthyretin amyloidosis now with a second new treatment option are available when the....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-75"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-75#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022610\/edited-notizia.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022610\/edited-notizia.png","width":686,"height":350},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022610\/edited-notizia-300x153.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Akcea Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alnylam Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">American Journal of Pathology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Brexit<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">European Union (EU)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Food and Drug Administration<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gardasil 9 vaccine<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">human papillomavirus (HPV) infection<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ionis pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">King&#039;s College London<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Merck &amp; Co<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">neurodevelopmental disorders<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Onpattro&#039;<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Orphan<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">postnatal immune<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">prenatal inflammation<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Queen&#039;s University Belfast<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">severe gut inflammation<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Tegsedi<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">The Lancet Oncology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">transthyretin amyloidosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">UK cancer research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">University of Leeds<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Akcea Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Alnylam Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">American Journal of Pathology<\/span>","<span class=\"advgb-post-tax-term\">Brexit<\/span>","<span class=\"advgb-post-tax-term\">European Union (EU)<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Food and Drug Administration<\/span>","<span class=\"advgb-post-tax-term\">Gardasil 9 vaccine<\/span>","<span class=\"advgb-post-tax-term\">human papillomavirus (HPV) infection<\/span>","<span class=\"advgb-post-tax-term\">Ionis pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">King&#039;s College London<\/span>","<span class=\"advgb-post-tax-term\">Merck &amp; Co<\/span>","<span class=\"advgb-post-tax-term\">neurodevelopmental disorders<\/span>","<span class=\"advgb-post-tax-term\">Onpattro&#039;<\/span>","<span class=\"advgb-post-tax-term\">Orphan<\/span>","<span class=\"advgb-post-tax-term\">postnatal immune<\/span>","<span class=\"advgb-post-tax-term\">prenatal inflammation<\/span>","<span class=\"advgb-post-tax-term\">Queen&#039;s University Belfast<\/span>","<span class=\"advgb-post-tax-term\">severe gut inflammation<\/span>","<span class=\"advgb-post-tax-term\">Tegsedi<\/span>","<span class=\"advgb-post-tax-term\">The Lancet Oncology<\/span>","<span class=\"advgb-post-tax-term\">transthyretin amyloidosis<\/span>","<span class=\"advgb-post-tax-term\">UK cancer research<\/span>","<span class=\"advgb-post-tax-term\">University of Leeds<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Oct 9, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Oct 9, 2018 5:07 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3340","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3340"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3340\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3366"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3340"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3340"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3340"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3340"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3340"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}